DPYD genotype information can be utilized to predict DPD metabolic activity, which can be used as an aid in determining a therapeutic strategy for drugs that are metabolized by DPD.

This is a pharmacogenomic test associated with 5-fluorouracil and capecitabine drug sensitivity. Biallelic variation in the DPYD gene is also associated with dihydropyrimidine dehydrogenase deficiency.

Insist that your oncologist test you for DPD deficiency prior to starting chemotherapy with 5-FU/capecitabine. This will help determine if the treatment is one you can tolerate.

What is the DPYD test? The DPYD test is a simple blood test. It is sometimes called a DPD test. The blood test checks for the gene changes that are most likely to cause low levels of the DPD enzyme.

Predicts risk of dose-related toxicity to 5-FU therapy. New York DOH Approval Status Indicates whether a test has been approved by the New York State Department of Health.

Jun 24, 2025 · Who should have DPD testing? Because DPD mutations occur in less than 3% of the population, testing is usually not required unless a patient has an adverse reaction during treatment …

However, there are no physical symptoms of DPD deficiency, so a DPYD gene test is the only way to find out if you have a deficiency. The results of this test will help your oncologist plan the best …

Is there a test to check for DPD deficiency? All people having 5FU or capecitabine should have a blood test before their treatment to check if they have a DPD deficiency.

Supplementary test information for Dihydropyrimidine Dehydrogenase (DPYD) such as test interpretation, additional tests to consider, and other technical data.

What do my DPYD test results mean? For a DPYD phenotype test, your results will be reported as normal DPD enzyme activity, decreased DPD enzyme activity (partial DPD deficiency), or absent …